Psyched Wellness CEO Jeff Stevens speaks to Psychedelic Health about how the company has launched the first legal Amanita muscaria extract available for sale in the United States.
Researchers at the University of Alabama, Birmingham, say the study findings demonstrate the critical role of the protein Tiam1 in the pathophysiology of chronic pain-induced mood...
Diamond Therapeutics has received approval from Health Canada to carry out a Phase 2 low-dose psilocybin trial for the treatment of generalised anxiety disorder (GAD) on...
Small Pharma has reported positive top-line results from its Phase 2a Trial of SPL026 in Major Depressive Disorder (MDD).
Awakn Life Sciences has initiated an investigative study to establish the dissociative effect of a proprietary and patent pending formulation of (S)-ketamine and an optimised route...
Cybin has announced key highlights from its study evaluating Kernel’s Flow wearable technology to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics.
The Energia Foundation, an organisation working at the forefront of healthcare and social movements, hosted the House of Health in Davos, Switzerland from 15 to 20...
Psyence Group has confirmed that it has exported purified pharmaceutical-grade psilocybin mushroom extract to its Contract Development & Manufacturing Organisation (CDMO) partner in the UK.
Results from MAPS PBC’s study have demonstrated a biological correlation between a reduction in PTSD severity and treatment with MDMA-assisted therapy in veterans and first responders.
Peter Reitano, CEO of Gwella, speaks to Psychedelic Health about the company’s mission to provide education on psychedelics and raise acceptance of the compounds beyond mental...